United States of America based
Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we hope to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to quickly and efficiently build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for new cures—to dramatically improve patients’ lives.
Posts Mentioning This Company
We are developing next-generation technologies to optimize key components of our AAV-based gene therapies, including redosing, transgene regulation and capsid development.
No pipelines published yet
No services posted yet